Say what, beta-blockers for asthma?

American Journal of Respiratory Cell and Molecular Biology

Volumn 38, Issue 3, 2008, Pages 249-250

  Chupp, Geoffrey L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; METOPROLOL; NADOLOL; PROPRANOLOL; CYTOKINE; MUCIN; OVALBUMIN; PROPANOLAMINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; EDITORIAL; HUMAN; NONHUMAN; RESPIRATORY TRACT DISEASE; ANIMAL; CHEMISTRY; DISEASE MODEL; INFUSION PUMP; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG LAVAGE; METABOLISM; MOUSE; NOTE; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; INFUSION PUMPS; INJECTIONS, INTRAPERITONEAL; MICE; MUCINS; NADOLOL; OVALBUMIN; PROPANOLAMINES; REPRODUCIBILITY OF RESULTS;

EID: 40649121045     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0001ED     Document Type: Editorial

References (7)

1. Hajar R. The invention of propranolol. Heart 2000;1:321-323.
2. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
3. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, et al. Chronic exposure to beta-blockers attenuates inflammation andmucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008;38:256-262.
4. Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, Giles H, Shardonofsky FR, Bond RA. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 2004;101:4948-4953.
5. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008;21:134-141.
6. Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007;27:684-690.
7. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127:818-824.